The conundrum of treating dermatologic adverse effects in response to treatment with amivantamab for EGFR-mutated NSCLC was discussed in a recent Frontline Forum.
ONCOLOGY® Companion, Volume 38, Supplement 7
A panel of experts in multiple myeloma discussed strategies for sequencing novel bispecific antibodies and CAR T-cell therapies for patients with relapsed/refractory disease.
Experts in multiple myeloma discussed the evolving role of CAR T-cell therapy for patients with relapsed/refractory disease.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
3
FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma
4
Leveraging Novel Software to Further Improve Personalized Cancer Care
5
